Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials

Giorgio V. Scagliotti; Cesare Gridelli; Filippo de Marinis; Michael Thomas; Mircea Dediu; Jean-Louis Pujol; C. Manegold; Belén San Antonio; Patrick Peterson; William J. John; Nadia Chouaki; Carla Visseren‐Grul; Luis Paz‐Ares

doi:10.1016/j.lungcan.2014.07.005

Keywords

PemetrexedMedicineInternal medicineOncologyLung cancerPopulationCisplatinPhases of clinical researchPlaceboAdverse effectMaintenance therapyChemotherapySurgeryPathology

Affiliated Institutions

Related Publications

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Filippo de Marinis , Mircea Dediu +14 more

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0....

2013 Journal of Clinical Oncology 626 citations

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes

Pascale Tomasini , Fabrice Barlési , Céline Mascaux +1 more

Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related death, and the treatment of advanced NSCLC relies on systemic treatments. During the last decade,...

2016 Therapeutic Advances in Medical Oncology 63 citations

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Shirish M. Gadgeel , Delvys Rodríguez‐Abreu , Giovanna Speranza +23 more

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo ...

2020 Journal of Clinical Oncology 1095 citations

IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.

M. Pérol , Clarisse Audigier-Valette , Olivier Molinier +17 more

9003 Background: Benefit coming from maintenance treatment appears greater for switch maintenance in pts with disease stabilization (SD) while it might be larger for continuatio...

2017 Journal of Clinical Oncology 6 citations

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Roy S. Herbst , Giuseppe Giaccone , Joan H. Schiller +14 more

Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, m...

2004 Journal of Clinical Oncology 1714 citations

Publication Info

Year: 2014
Type: article
Volume: 85
Issue: 3
Pages: 408-414
Citations: 23
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    Giorgio V. Scagliotti, 
                                
                                    Cesare Gridelli, 
                                
                                    Filippo de Marinis
                                
                                et al.
                            
                            (2014). 
                            Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. 
                            Lung Cancer
                            , 85
                            (3)
                            , 408-414.
                            https://doi.org/10.1016/j.lungcan.2014.07.005
                        

Identifiers

DOI: 10.1016/j.lungcan.2014.07.005